COVID-19 infection: from stress-related cortisol levels to adrenal glands infarction

MIHAELA POPEȘCU1), DANA CRISTINA TERZEA2), MARA CARSOTE3), ALICE ELENA GHENEA4), ANDREI COSTACHE5), IULIAN ALIN SILVIU POPEȘCU6), VIOREL BICIȘCU6), CRISTINA JANA BUSUIOC7), ADINA MARIANA GHEMIGIAN3)

1)Department of Endocrinology, University of Medicine and Pharmacy of Craiova, Romania
2)Department of Pathology and Immunohistochemistry, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; Department of Pathology and Immunohistochemistry, Monza Onco Team Diagnostic, Bucharest, Romania
3)Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Endocrinology, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania
4)Department of Bacteriology–Virology–Parasitology, University of Medicine and Pharmacy of Craiova, Romania
5)PhD Student, Doctoral School, University of Medicine and Pharmacy of Craiova, Romania
6)Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania
7)Department of Histology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania

Abstract
Cortisol is a key element in acute stress including a severe infection. However, in coronavirus-associated disease, 20% of subjects experience hypocortisolemia due to direct or immune damage of pituitary and adrenal glands. One extreme form of adrenal insufficiency is found in 2/3 of cases with viral and post-viral adrenal infarction (AI) (with/without adrenal hemorrhage) that is mostly associated with a severe coronavirus disease 2019 (COVID-19) infection; it requires prompt glucocorticoid intervention. Some reports are incidental findings at computed tomography (CT)/magnetic resonance imaging (MRI) scans for non-adrenal complications like pulmonary spreading and others are seen on post-mortem analysis. This is a review of PubMed-accessible, English papers focusing on AI in addition to the infection, between March 1, 2020 and November 1, 2021. Exclusion criteria were acute adrenal insufficiency without the histopathological (HP) and/or imaging report of adrenal enlargement, necrosis, etc., respective adrenal failure due to pituitary causes, or non-COVID-19-related adrenal events. We identified a total of 84 patients (different levels of statistical evidence), as follows: a retrospective study on 51 individuals, two post-morthern studies comprising nine, respectively 12 patients, a case series of five subjects, seven single-case reports. HP aspects include necrosis associated with ischemia, cortical lipid degeneration (+/- focal adenomas), and infarcts at the level of adrenal cortex, blood clot into vessels, acute fibrinoid necrosis in arterioles and capsules, as well as subendothelial vacuolization. Collateral potential contributors to adrenal damage are thrombotic events, coagulation anomalies, antiphospholipid syndrome, endothelial dysfunction, severe COVID-19 infection with multiorgan failure, etc. Clinical picture is variable from acute primary adrenal insufficiency to asymptomatic or mild evolution, even a retrospective diagnostic; it may be a part of long COVID-19 syndrome; glucocorticoid therapy for non-adrenal considerations might mask cortisol deficient status due to AI/hemorrhage. Despite its rarity, the COVID-19-associated AI/hemorrhage represents a challenging new chapter, a condition that is essential to be recognized due to its gravity since prompt intervention with glucocorticoid replacement is lifesaving.

Keywords: stress, COVID-19, cortisol, adrenal hemorrhage, adrenal tumor.

Introduction
The concept of adrenal infarction/hemorrhage

Adrenal infarction (AI) may associate or not adrenal hemorrhage; this is a very rare disease for both adults and pediatrics; it is caused or associated with sepsis, abdominal trauma, coagulation defects or use of anticoagulant medication, general conditions associated a high risk of hemorrhage (as active cancers, and neonatal stress, etc.) [1–4]. In one series, 40% of cases that were diagnosed with adrenal hemorrhage had a previous non-functioning adenoma at adrenal cortex level [1] (Figure 1, A and B). An adenoma at the level of adrenal cortex might not be prior recognized; adrenal hemorrhage is sometimes the first presentation of the patient; histopathological (HP) report may identify both the tumor and the adrenal infection/hemorrhage; the immunohistochemistry (IHC) report on remnant adrenocortical adenoma might help its characterization [5–10] (Figure 2, A–D). Exceptional situations include syndromic context like TAFRO syndrome (which includes thrombocytopenia, anasarca, reticulin fibrosis of the bone marrow, renal dysfunction, and organomegaly) [11].

The clinical presentation of AI varies from acute adrenal insufficiency (in two thirds of cases – especially with bilateral lesions present – if left untreated it has a fatal evolution) and/or shock up to an incidental retrospective finding at different imaging evaluations, either as a necrotic adrenal mass, active hemorrhage or cystic tumor-like aspect or a post-mortem, HP report [12–14].

This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
COVID-19 infection and endocrine glands

Crucial effects on endocrine glands and neuroendocrine system are related to the coronavirus disease 2019 (COVID-19) infection, with a heterogeneous pattern of presentation; among major targets are pancreas, pituitary gland, thyroid, adrenal glands, and testes [15, 16]. The presence of diabetes mellitus (DM) or high blood pressure (HBP) are among the factors with a poor prognostic, as also found, for instance, for advanced age, active smoking, chronic renal failure, co-presence of prior cardio-cerebrovascular conditions [17].

IHC studies showed positive reaction for angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) at cells of the adrenal cortex [18, 19]. The clinical presentation is mostly related to endocrine
dysfunction, meaning low cortisol levels in critical patients [18]. Acute onset of COVID-19 infection might involve a switch from a chronic to adrenal form of primary adrenal insufficiency, previously known or unknown [20, 21]. Physiologically, angiotensin system serves for maintaining normal blood pressure and adequate remodeling of blood vessels walls [21, 22].

**Aim**

Our purpose was to correlate certain aspects of adrenal response in relationship with COVID-19 infection. This type of infection is regarded as a major stress for the human body (which was reflected by cortisol levels), thus it involves severe complications of adrenal glands as AI with or without hemorrhage.

**Materials and Methods**

Original data includes a narrative review of coronavirus infection with adrenal involvement (especially focusing on cortex-produced cortisol hormone). This is a review of PubMed-accessible, English scientific literature including only in extenso papers focusing on AI with or without hemorrhage in addition to the infection with coronavirus (between March 1, 2020 and November 1, 2021). The search words are in different combinations “COVID-19”, “coronavirus”, “SARS-CoV-2” and “adrenal”, “cortisol”, “stress”, “adrenal hemorrhage”, “adrenal infarction”.

Exclusion criteria were acute adrenal insufficiency without the HP and/or imaging report of adrenal enlargement, necrosis, and adrenal failure due to pituitary causes, and also non-COVID-19-related cases. Overall, 97 references are cited at different subsections. Figures 1 and 2 represent captures of pathological reports and IHC analysis that are based on authors’ clinical experience. The patients agreed to anonymously use their medical records.

**Literature data**

We identified articles regarding COVID-19 infection and AI with different levels of statistical significance, as follows: seven case reports, a case series of five individuals, a retrospective study on 51 subjects, two post-mortem studies comprising nine, respectively 12 patients (a total of 84 adults with different types of AI +/- hemorrhage +/- adrenal insufficiency).

COVID-19 infection: adrenal involvement

**Cortisol as stress hormone**

COVID-19 infection may be regarded as an acute stress of the human body, thus the outburst of stress hormones like cortisol is expected [23]. During acute stress, the general biochemistry and endocrine panel includes increased traditional biomarkers of inflammation (like fibrinogen, C-reactive protein), changes of leptin, adrenalin, procalcitonin, ferritin, lactate dehydrogenase levels, a new dynamics of interleukins (ILs) profile, etc. [24, 25]. Other data particularly concerning COVID-19 infection, showed, for instance, as cortisol associates with inflammation markers, so is total testosterone and calculated free testosterone in females with pneumonia due to more intense adrenal cortex activity [26]. Particular aspects related to coronavirus infection-associated stress include anomalies of coagulation profile in addition to platelets damage as reflected by increased D-dimers, fibrinogen, and coagulation factor VIII, as well as low anticoagulant protein S and activated protein C, reduced coagulation factor XII [27].

**Hypocortisolism concerning COVID-19 infection**

Immune response to the virus may damage pituitary gland, regardless there is a prior hypophysal known tumor or not, either functioning or nor (including the potential of associated morbidities like DM or HBP) [28]. Post-viral necrosis and low pituitary hormones has been described in viral hypophysitis, as traditionally seen in other circumstances like spontaneous necrosis/apoplexy, dopamine agonists and somatostatin analogues use for somatotropinoma or prolactinoma, Sheehan syndrome, etc. [28–30].

In severe forms of coronavirus infection, hypocortisolemia was found in approximately one fifth of the patients, depending on study [31]. This is due to the presence of antibodies against adrenocorticotropic hormone (ACTH) due to hypophysitis causing secondary adrenal insufficiency or to adrenalitis [32].

One transversal, retrospective, single-center study showed that subjects with moderate-to-severe COVID-19 infection have statistically significant more frequent hypocortisolism versus subjects with mild coronavirus infection (which was defined in this study as an oxygen saturation of more than 94% and no other comorbidities) [33]. Central-related low levels of cortisol may also associate secondary hypothyroidism due to COVID-19 infection; during acute phase, it is difficult to assess if permanent glucocorticoid and/or Levothyroxine replacements will be required [34, 35].

After the recovery from COVID-19 infection, some authors also found a recovery of adrenal function. As an example, there is a prospective, observational study on 70 adults who were infected three months prior and had normal basal cortisol levels, as well as post-Synacthen test (performed with an intravenous dose of 250 μg) [34]. However, other authors suggested a potential adrenal involvement in long COVID-19 syndrome associating asthenia, fatigue, and even cognitive impairment within the first weeks up to several months after infection [36–39].

**COVID-19 infection: glucocorticoids use**

Generally, glucocorticoid therapy is highly recommended for its strong anti-inflammatory effect [40]. Early during pandemic, a particular candidates’ group was identified in subjects with severe respiratory distress symptoms and/or immunosuppression, septic shock (representing 5% of all infected cases) [41]. Systemic glucocorticoid medication is associated, depending on severity and comorbidity, with a large panel of intervention like drugs from antiviral medication, oxygen therapy, antibiotics, anticoagulants to extracorporeal blood purification therapy (EBPT) to immunomodulating drugs, renal replacement therapy, etc. [41–45].

Systemic corticosteroids administration reduces all-cause mortality in subjects hospitalized for coronavirus infection, and probably decreases the need for ventilation [46]. Also, their use was correlated to a reduced rate of conversion from a mild case into a severe one [47].
In cases with COVID-19 infection, as generally known, large doses and long-term glucocorticoid therapy are expected to associate a multitude of side effects from HBP, bone damage in terms of bone turnover, reduced bone mineral density and abnormal microarchitecture as reflected by trabecular bone score, digestive anomalies, glucose variations, etc. [48, 49]. Also, glucocorticoid treatment is indicated in critically ill COVID-19-positive patients, thus increasing the risk of venous thromboembolism with a poor outcome [50, 51]. As an alternative, Methylprednisolone or Dexamethasone in high dose as pulse therapy may reduce the side effects [51]. Moreover, a corticosteroids regime of short-term was proposed in addition to the first dose of vaccination to reduce the reactivity tendency surrounding the immunization against COVID-19; however, this type of approach still needs validation [52].

**AI and COVID-19 infection**

**HP aspects**

The virus uses ACE2 as a receptor; we already know that the receptor is displayed all over the human body, including in arterial and venous cells of endothelial type, also in adrenal glands [53]. Even before current pandemic outbreak, the severe acute respiratory syndrome coronavirus (SARS-CoV) family was known to target adrenal glands, mostly at cortex level, representing a clear pathogenic loop of the virus, thus cortisol levels are expected to be affected [54].

AI goes with or without hemorrhage, having different extends which are translated into endocrine anomalies of adrenal cortex especially in severe situations [55–57]. Associated adrenal insufficiency may be the main feature of the clinical picture or it may represent only a small part of an otherwise complicated presentation due to severe COVID-19 infection, especially with lung or multiorgan involvement [55–57].

One post-mortem study showed various adrenal lesions in 46% of the patients (a cohort of 28 subjects who died because of coronavirus complications): seven individuals with necrosis associated with ischemia, four persons with cortical lipid degeneration (two cases of them also associating lesions of focal adenralitis), two subjects with adrenal necrosis associated with hemorrhage, and one 70-year-old male with isolated lesions of focal adrenalitis [58]. Interestingly, one of the cases with necrosis also had lesions of adrenocortical carcinoma [58]. Another post-mortem study showed a misalignment between general involvement and particular aspects concerning adrenal damage where a complex panel of changes is described: infarcts at the level of adrenal cortex, thrombi into vessels, acute fibrinoid necrosis at arterioles and glands capsule, as well as sub-endothelial vacuolization, etc. [59].

**Contributor factors**

Previous thrombotic events are an essential contributor factor [60]. Other collateral elements might be autoimmune conditions of endocrine and non-endocrine type, liver anomalies (including of coagulation factors), anti-phospholipid syndrome (APLS); endothelial dysfunction in severe shock accompanying coronavirus infection has been described including in pediatric population [60, 61]. Endothelial injury, inflammation and hypoxia may similarly cause myocardial infarction [62–64]. Most probably, the fact that COVID-19 infection induced positive anti-phospholipid antibodies represents the key element which was also described in patients without coronavirus infection [65]. However, the actual level of statistical evidence is low, and we currently consider AI as a more complicated puzzle with multifactorial pathogenicity [60].

AI may be found in patients with less severe coronavirus infection, but also, it is found accompanying the general damage due to cytokine storm, as an excessively increased status of acute inflammation in critically ill infected subjects (between 1% and 5% of COVID-19 patients depending on study), in cases with multiorgan failure underling severe thromboembolic events like ischemic stroke, myocardial infarction, acute renal failure, vasculitis, etc., thus involving vessels that are connected with adrenal glands [66]. The severe clinical picture is heterogeneous since multiple systems are damaged. For instance, in one case of a 50-year-old male, bilateral adrenal hemorrhage was first accidently detected at computed tomography (CT) scan for COVID-19 pneumonia, followed by clinical manifestation of adrenal insufficiency with hypotension, which was unfortunately followed by multiple thrombosis including massive pulmonary embolism [67]. This case also associates a prior diagnosis of adrenal tumor, which is exceptionally found until now in patients with COVID-19-positive adrenal hemorrhage [67]. Another 48-year-old male with a prior diagnosed of APLS who was under therapy with vitamin K antagonists at the moment of COVID-19 infection developed ischemia at the level of left toes due to artery occlusion, and he was synchronously diagnosed with adrenal hemorrhage before the switch was done for low-molecular-weight heparin (Enoxaparin) [68]. Another 66-year-old female who was previously known with APLS was also admitted for active COVID-19 infection and adrenal hemorrhage-related adrenal insufficiency followed by a thrombosis at the level of renal vein, an evolution that confirms so called “two-hit’’ theory [69].

**Clinical elements**

Digestive symptoms and cardiovascular deterioration may be related to the infection or to adrenal infraction [64]. Digestive involvement (like abdominal pain, diarrhea, nausea, vomiting) during COVID-19 infection is reported in almost half of cases, typically after pulmonary symptoms [70, 71]. These are caused by the fact that ACE2 receptors are located at the level of gastrointestinal system, and also at pancreas [72, 73]. On the other hand, the clinical presentation of acute adrenal insufficiency includes hypotension, collapse, nausea, vomiting, abdominal pain, fever, lethargy, confusion, etc., which may mimic a COVID-19 infection with digestive presentation [73]. However, an infection itself (of any type) may be the trigger of an acute form of primary adrenal failure [73]. The incidence of adrenal crisis in general population is 10/100 individual-years (a mortality of 0.5/100 patient-years) [73]. Prompt recognition and adequate glucocorticoid therapy is lifesaving [73].

Recently, a new potential differential diagnostic of acute adrenal failure with abdominal pain was established in relationship with coronavirus infection: multisystem inflammatory disease in adults (MIS-A), syndrome that was initially described in children (MIS-C syndrome), with a Kawasaki-like pattern of presentation [74, 75]. MIS-A or
MIS-C syndrome causes abdominal pain, cardiac failure, shock, fever, increased markers of inflammation following the actual COVID-19 infection or being synchronous to it [76, 77]. This complication of acute respiratory distress syndrome increases the mortality; the use of immunoglobulin treatment, steroids, biotherapy like anti-IL antibodies may improve the prognosis to some extent [78, 79].

In one retrospective study, which aimed to identify the adrenal lesions suggestive for infarction in acute coronavirus infection with severe lung complications, the adrenal lesion was incidentally detected in 23% of subjects (male predominance, a mean age of 67±11 years) [80]. Only 8% of cases had a confirmation of endocrine panel suggestive for adrenal insufficiency; the accidental CT finding was correlated with a more prolonged hospital stay [80].

Another retrospective study on nine adult UK subjects (with mean age of 73 years) with SARS (due to coronavirus infection with severe lung complications, the adrenal lesion was incidentally detected in 23% of subjects (male predominance, a mean age of 67±11 years) [80]. Only 8% of cases had a confirmation of endocrine panel suggestive for adrenal insufficiency; the accidental CT finding was correlated with a more prolonged hospital stay [80].

A 70-year-old male case was diagnosed with bilateral adrenal hemorrhage, while he was under glucocorticoid medication in addition to a complex regime for COVID-19 bilateral bronchopneumonia [85].

Table 1 – The PubMed-based, English language, full-length papers published between March 1, 2020 and November 1, 2021 concerning COVID-19 infection and AI with or without adrenal hemorrhage, with or without adrenal insufficiency related to COVID-19 infection

| No. | Authors / reference | Type of study | No. of patients / age [years] / sex | Presentation | Endocrine aspects | COVID-19 aspects | Observations |
|-----|---------------------|---------------|-------------------------------------|--------------|------------------|-----------------|--------------|
| 1.  | Freire Santana et al. / [58] | Post-mortem study (autopsy) | 12 out of 28 (46%) patients with adrenal lesions | Autopsy diagnostic | No adrenal insufficiency based on cortisol levels (sample within 1–2 days before death) | COVID-19 as cause of death | Prior diagnostic of APLS |
| 2.  | Iuga et al. / [59] | Case series | 5 patients / between 59 and 90 / F/M ratio: 1/4 | Autopsy diagnostic | Not available | COVID-19 as cause of death | 2 patients died of cardiac arrest at emergency room |
| 3.  | Machado et al. / [60] | Case report | 1 patient / 46 / F | Abdominal pain, hypotension, skin hyperpigmentation | Na↓, Cortisol↓, ACTH↑, Aldosterone↓ | CT scan: bilateral adrenal enlargement (infarction) | Other contributors: prior autoimmune hepatitis, de novo positive anti-phospholipid antibodies |
| 4.  | Kumar et al. / [64] | Case report | 1 patient / 70 / F | Fatigue, abdominal pain, vomiting, diarrhea | On admission: random ACTH, cortisol, K normal → then adrenal insufficiency | Synchronous with COVID-19 pneumonia | Other elements: negative anti-cardiolipin antibodies, history of HBP, hypercholesterolemia |
| 5.  | Elkhouly et al. / [67] | Case report | 1 patient / 50 / M | Fever, malaise, dyspnea, cough, bilateral flank discomfort | Adrenal lesion was accidentally detected at CT | COVID-10 pneumonia, further complicated with deep vein thrombosis, massive pulmonary embolism causing the patient’s death | Previous diagnostic of HBP and right adrenal tumor |
| 6.  | Maria et al. / [68] | Case report | 1 patient / 49 / M | Fever, cough, myalgia + sudden abdominal pain | Not available | COVID-19 pneumonia and limb arterial ischemia | Prior diagnostic of APLS |

The patient was under vitamin K antagonists at the moment of infection.
### Discussions

Our systematic review represents a new chapter in medical field, once the COVID-19 pandemic started and changed the entire worlds, not just from a strictly medical perspective [24–86].

Early during pandemic, the endocrine glands were found to be affected by the coronavirus, and the adrenal glands represent a hallmark of human body survival under different circumstances on daily basis and acute, as well as chronic stress. Assessment of cortisol levels are essential tools for practitioners to assess to body capacity to adjust under these circumstances (unless the patient is already under glucocorticoid medication). The extreme clinical presentation of adrenal involvement in a patient who is infected with coronavirus or is a survivor of disease is adrenal infarction, especially associating adrenal hemorrhage. The traditional HP panel is a milestone for this condition; however, the early recognition (based on signs and symptoms of newly detected adrenal insufficiency, as well as imaging findings like enlargement of one or both glands and blurring pattern at CT scan) and further on therapy with systemic corticoids, are essential for prognostic/survival [24–86].

In relationship with COVID-19 infection, the cases that are reported so far by the medical community concern adult patients who either had a severe infection with a multiorgan failure or are during post-viral period of time. Also, valuable data are provided by post-mortem analysis in subjects who died from the disease. The recognition of clinical entity may be masked by severe general involvement of multiple organs or by the fact that the patient is already under glucocorticoid medication for a different (non-adrenal) complication, thus the lifesaving therapy is already provided to the patient. Also, after surpassing the acute phase, it remains this debatable issue of long-term need for oral corticoids, including the utility of assessing the hormonal tests, which are specific for cortisol/ACTH levels, including stimulation tests, which might indicate the need of glucocorticoids even in small doses or their supplementation under different stress circumstances [24–86].

Even though current level of statistical evidence is not reliable for large meta-analysis, the topic is new, it dates from 2020–2021, and it is essential to be communicated to the practitioners at the level we are currently aware of [1–86].

Adrenal hemorrhage has been exceptionally described in relationship with medulla; a first case of pheochromocytoma-related hemorrhage in a 62-year-old male admitted for coronavirus-associated pneumonia was the initial sign that led to the detection of the adrenal tumor [87].

Vaccine against coronavirus might also trigger an AI. One of the mechanisms that link COVID-19 adenoviral vector-based vaccination to immune (vaccine-induced) thrombotic thrombocytopenia that may cause acute complications like acute renal failure due to thrombosis or bleeding due to low platelets count [88–90]. This may also represent the pathogenic factor of adrenal hemorrhage, as several

| No. | Authors / reference | Type of study | No. of patients / age [years] / sex | Presentation | Endocrine aspects | COVID-19 aspects | Observations |
|-----|---------------------|---------------|-----------------------------------|--------------|-------------------|-----------------|-------------|
| 7   | Frankel et al. / [69] | Case report   | 1 patient / 66 / F                | Fever, dyspnea, abdominal pain, nausea, vomiting | Na↓, Basal cortisol↓, ACTH↑ | Synchronous with COVID-19 infection | CT: enlargement of adrenal glands |
| 8   | Leyendecker et al. / [80] | Retrospective study (March 9–April 10, 2020) | 51 out of 219 (23%) patients with CT for lung involvement / mean age 67±11 / 71% M | Detection as incidental CT finding | Correlation with an longer hospital stay versus without | 8% adrenal insufficiency | Synchronous with COVID-19 with severe/critical lung disease | CT: bilateral lesions in 88% of cases |
| 9   | Hanley et al. / [81] | Retrospective study (post-mortem) (March 1–April 30, 2020) | 9 patients / 73 / 9 patients / (IQR 52–79) / 7 M, 3 F | Death due to SARS | | | Adrenal involvement confirmed at post-mortem analysis |
| 10  | Álvarez-Troncoso et al. / [85] | Case report | 1 patient / 70 / M | Fever, chills, asthenia, constipation, malaise, generalized weakness, anorexia, nausea, vomiting | Na↓ | Synchronous with COVID-19 bilateral bronchopneumonia | CT: bilateral enlargement of adrenal glands (with blurring aspect) |
| 11  | Sharrack et al. / [86] | Case report | 1 patient / 53 / M | Fever, dyspnea, pleuritic chest pain | Normal short Synacthen test | COVID-19-related bilateral pulmonary embolism | CT: right adrenal hemorrhage confirmed during infection and remitted at CT scan performed after five months |

ACTH: Adrenocorticotropic hormone; AI: Adrenal infarction; APLS: Antiphospholipid syndrome; COVID-19: Coronavirus disease 2019; CT: Computed tomography; F: Female; HBP: High blood pressure; IQR: Interquartile range; K: Potassium; M: Male; Na: Sodium; SARS: Severe acute respiratory syndrome.
cases reported it in 2021 [91–94]. Another case of a 54-year-old female presented post-vaccine disseminated intravascular coagulation due to multiple-site thrombosis including brain, lung, and bilateral adrenal hemorrhage [95]. Moreover, a first case of pleochromocytoma detection after COVID-19 vaccine was recently reported; this 63-year-old male patient had no previous history of an adrenal tumor until adrenergic crisis starting within 24 hours since vaccination [96]. Overall, despite limited level of statistical evidence, it is mandatory to address to topic of adrenal involvement amid COVID-19 pandemic on a multidisciplinary perspective.

Conclusions
Cortisol is a key element in acute stress including a severe infection. However, in coronavirus-associated infection, hypocortisolemia is found due to direct or immune damage at pituitary and adrenal glands. One extreme form of adrenal insufficiency is COVID-19-related AI with/without hemorrhage that is mostly associated with a severe form of infection; it requires prompt glucocorticoid intervention. Some of the reports are incidental findings during CT for pulmonary lesions and others are post-mortem intervention. Some of the reports are incidental findings extreme form of adrenal insufficiency is COVID-19-related immune damage at pituitary and adrenal glands. One first case of pheochromocytoma detection after COVID-19 had no previous history of an adrenal tumor until adrenergic crisis starting within 24 hours since vaccination [96].

Conflict of interests
The authors declare that they have no conflict of interests.

Acknowledgments
This paper was supported by 26/SC/23.06.2021 grant: “Assessment of the neuroendocrine effects of stress on a school population during the COVID-19 pandemic”.

References
[1] Kanawacka IM, Oboloľczik L, Sworczak K. Adrenal hemorrhage: a single center experience and literature review. Adv Clin Exp Med, 2018, 27(5):681–687. https://doi.org/10.17219/acem/68 897 PMID: 29616752
[2] An P, Chen K, Yang QG, Dou JT, Chen YL, Jin XY, Wang XL, Mu YM, Wang QS. Diffuse large B cell lymphoma with bilateral adrenal and hypothalamic involvement: a case report and literature review. World J Clin Cases, 2019, 7(3):4075–4083. https://doi.org/10.12998/wjcc.v7.i23.4075 PMID: 31832411 PMCID: PMC6908562
[3] Toli MS, Ghiri P, Bartoli A, Caputo C, Laudani E, Masoni F, Caraceni A, Meloni S. Adrenal hemorrhage in newborn: how, when and why – from case report to literature review. Ital J Pediatr, 2019, 45(1):58. https://doi.org/10.1186/s13052-019-0651-9 PMID: 31068206 PMCID: PMC6507044
[4] Jimidar N, Ysebaert D, Twickler M, Spinhoven M, Damks, Jorens PG, Alonso R, Sandru F, Dumitrascu MC, Ghemigian A, Carsote M. Inside of an adrenal cyst. Medical Image Database, 2021, 4(1):31–32. https://doi.org/10.33996/mid.v4i1.104 https://www.medicalimage. ro/index.php/MID/article/view/104
[5] Valea A, Carsote M, Petrova E, Dumitrascu MC, Sandru F, Pale skin: an adrenal cancer? Rom J Med Pract, 2019, 14(4):460– 463. https://doi.org/10.37897/RJMP.2019.4.24 https://rjmp.com.rjmp-vol-xiv-nr-4-an-2019/
[6] Dumitrascu MC, Trandafir AI, Petrova E, Ghemigian A, Carsote M, Sandru F, Mehedintu C. Adrenal hemorrhage. Rom J Med Pract, 2021, 16(4):413–421. https://doi.org/10.37897/RJMP.2019.1.4.2 https://rjmp.com.rjmp-vol-xiv-nr-4-an-2021/
[7] Dumitrascu MC, Sandru F, Carsote M, Petrova E, Ghemigian A, Carsote M. Adrenal surgery amid COVID-19 pandemic. Rom J Med Pract, 2021, 68(4):429–432. https://doi.org/10.37897/RJMP.2021.4.1.4 https://rjmp.com.rjmp-vol-xxvii-nr-4-an-2021/

Confronting the COVID-19 pandemic: from stress-related cortisol levels to adrenal glands infarction

References
[1] Kanawacka IM, Oboloľczik L, Sworczak K. Adrenal hemorrhage: a single center experience and literature review. Adv Clin Exp Med, 2018, 27(5):681–687. https://doi.org/10.17219/acem/68897 PMID: 29616752
[2] An P, Chen K, Yang QG, Dou JT, Chen YL, Jin XY, Wang XL, Mu YM, Wang QS. Diffuse large B cell lymphoma with bilateral adrenal and hypothalamic involvement: a case report and literature review. World J Clin Cases, 2019, 7(3):4075–4083. https://doi.org/10.12998/wjcc.v7.i23.4075 PMID: 31832411 PMCID: PMC6908562
[3] Toli MS, Ghiri P, Bartoli A, Caputo C, Laudani E, Masoni F, Caraceni A, Meloni S. Adrenal hemorrhage in newborn: how, when and why – from case report to literature review. Ital J Pediatr, 2019, 45(1):58. https://doi.org/10.1186/s13052-019-0651-9 PMID: 31068206 PMCID: PMC6507044
[4] Jimidar N, Ysebaert D, Twickler M, Spinhoven M, Damks, Jorens PG, Alonso R, Sandru F, Dumitrascu MC, Ghemigian A, Carsote M. Inside of an adrenal cyst. Medical Image Database, 2021, 4(1):31–32. https://doi.org/10.33996/mid.v4i1.104 https://www.medicalimage.ro/index.php/MID/article/view/104
[5] Valea A, Carsote M, Petrova E, Dumitrascu MC, Sandru F, Pale skin: an adrenal cancer? Rom J Med Pract, 2019, 14(4):460–463. https://doi.org/10.37897/RJMP.2019.4.24 https://rjmp.com.rjmp-vol-xiv-nr-4-an-2019/
[6] Dumitrascu MC, Trandafir AI, Petrova E, Ghemigian A, Carsote M, Sandru F, Mehedintu C. Adrenal hemorrhage. Rom J Med Pract, 2021, 16(4):413–421. https://doi.org/10.37897/RJMP.2019.1.4.2 https://rjmp.com.rjmp-vol-xiv-nr-4-an-2021/
CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr, 2021, 180(2):307–322. https://doi.org/10.1007/s00431-020-03766-6 PMID: 32803422 PMCID: PMC7429125

Leyendecker P, Ritter S, Riou M, Wackenthaler A, Meziani F, Roy C, Ohana M. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol, 2021, 31(2):895–900. https://doi.org/10.1007/s00330-020-07226-5 PMID: 32852586 PMCID: PMC7450155

Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou P, Corbett R, Goldin R, Al-Sarraj S, Abdolrasouli A, Swann OC, Bailion L, Penn R, Barclay WS, Vila P, Osborn M. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe, 2020, 1(6):e245–e253. https://doi.org/10.1016/S2666-5247(20)30115-4 PMID: 32844161 PMCID: PMC7440861

Chiperi LE, Ionescu AD, Marcu CT, Itu-Mureşan A. Hemophagocytic lymphohistiocytosis in a child with human immunodeficiency virus infection – a case report. Rom J Morphol Embryol, 2021, 62(1):279–282. https://doi.org/10.47162/RJME.62.1.29 PMID: 34609432 PMCID: PMC8597364

Paladugu S, Donato AA. Recommendations for caring for patients with severe and nonsevere COVID-19. Ann Intern Med, 2020, 173(2):J3. https://doi.org/10.7326/AJCP2020-7210-004 PMID: 32687760

Mattos-Silva P, Felix NS, Silva PL, Robba C, Battaglini D, Pelosi P, Rocco PRM, Cruz FF. Pros and cons of corticosteroid therapy in patients with severe and nonsevere COVID-19. Antibiotics (Kherson), 2020, 9(4):251–260. https://doi.org/10.1007/s40121-020-00432-7 PMID: 32659271 PMCID: PMC7351052

Al Rawahi B, Al-Balushi A, Al-Mazrouqi A, Al-Balushi N. Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine – a case report. Res Pract Thromb Haemost, 2021, 5(6):e12578. https://doi.org/10.1002/rth2.12578 PMID: 34466769 PMCID: PMC8385181

Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol, 2021, 193(3):365–370. https://doi.org/10.1111/bjh.17645 PMID: 34075578 PMCID: PMC8239625

Varona JF, García-Isidoro M, Moeinvaziri M, Ramos-López M, Fernández-Dominguez M. Primary adrenal insufficiency associated with Oxford–AstraZeneca ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Eur J Intern Med, 2021, 91:90–92. https://doi.org/10.1016/j.ejim.2021.06.025 PMID: 34256693 PMCID: PMC8271354

Taylor P, Allen L, Shririshnapalasuriy N, Stechman M, Rees A. Vaccine-induced thrombocytopenia and thrombosis with bilateral adrenal haemorrhage. Clin Endocrinol (Oxf), 2022, 91(1):26–27. https://doi.org/10.1111/cen.14548 PMID: 34235757 PMCID: PMC8444492

Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost, 2021, 19(7):1717–1775. https://doi.org/10.1111/jth.15347 PMID: 33877737 PMCID: PMC8250306

D’Agostino V, Caranci F, Negri O, Misafir M, Piscitelli V, Tuccillo B, Haji N Jr, Ali S, Wahashi EA, Khalid M, Ramamurthi K. Johnson and Johnson COVID-19 vaccination triggering pheochromocytoma multisystem crisis. Cureus, 2021, 13(9):e18196. https://doi.org/10.7759/cureus.18196 PMID: 34707965 PMCID: PMC8536310

Corresponding author
Mara Carsote, MD, PhD, Senior Lecturer of Endocrinology. Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, C.I. Parhon National Institute of Endocrinology, 34–36 Aviatorilor Avenue, Sector 1, 011683 Bucharest, Romania; Phone +40744–851 934, e-mail: carsote_m@hotmail.com

Received: April 4, 2022
Accepted: August 21, 2022